Keshu Zhou

机构：Wuhan University, Zhengzhou University, Henan Cancer Hospital, Henan Medical University · ORCID：0000-0001-5467-1377

发表论文 344 篇 · 总被引 2678 次 · h-index 24

代表论文

• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report (2025 · Blood · 被引 2)
• Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 1)
• Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study (2025 · Blood · 被引 1)
• CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D) (2025 · Blood · 被引 1)
• The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) (2025 · Blood · 被引 1)